Find Clinical Trial

An open-label safety and pharmacokinetic study of gevokizumab in subjects with Behçet’s disease uveitis


← Back
Study Phase

Phase 2

Therapeutic Area

Other

IndicationNon Infectious Uveitis
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

GEVOKIZUMAB,
S078989

Active Substance CodeS078989
Protocol CodeCL2-78989-001
ISRCTN CodeISRCTN15180871


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility